These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11364474)

  • 1. New treatment a cure? Moment of truth draws nigh.
    AIDS Alert; 1997 Aug; 12(8):90-2. PubMed ID: 11364474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication timetable setback.
    TreatmentUpdate; 1999 May; 11(3):3-4. PubMed ID: 11366780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of total and integrated HIV-1 DNA in peripheral CD4 lymphocytes and monocytes after long treatment with HAART.
    Calcaterra S; Cappiello G; Di Caro A; Garbuglia AR; Benedetto A
    J Infect; 2001 Nov; 43(4):239-45. PubMed ID: 11869061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In search of the Holy Grail: Martin Markowitz, M.D., on the dream of eradication.
    Markowitz M
    Res Initiat Treat Action; 1998 Apr; 4(2):9-13. PubMed ID: 11365230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antiretroviral therapy on apoptosis markers and morphology in peripheral lymph nodes of HIV-infected individuals.
    Ehrhard S; Wernli M; Kaufmann G; Pantaleo G; Rizzardi GP; Gudat F; Erb P; Battegay M
    Infection; 2008 Mar; 36(2):120-9. PubMed ID: 18379725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hidden HIV reservoirs: will eradication of the virus be possible?
    Gomez E
    Newsline People AIDS Coalit N Y; 1998 Mar; ():18-9. PubMed ID: 11367451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-2 taken to HAART.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
    Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
    Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GNB3 C825T polymorphism and response to anti-retroviral combination therapy in HIV-1-infected patients--a pilot study.
    Brockmeyer NH; Potthoff A; Kasper A; Nabring C; Jöckel KH; Siffert W
    Eur J Med Res; 2005 Nov; 10(11):489-94. PubMed ID: 16354603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of proviral HIV-1 184M/V in circulating CD4+ T-cells: a 90 days follow-up study after initiation/switch of HAART.
    Mohey R; Katzenstein TL; Black FT; Kjems J; Obel N
    Scand J Infect Dis; 2006; 38(2):119-23. PubMed ID: 16449003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
    Sankatsing SU; van Praag RM; van Rij RP; Rientsma R; Jurriaans S; Lange JM; Prins JM; Schuitemaker H
    Antivir Ther; 2003 Apr; 8(2):137-42. PubMed ID: 12741626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moods brighten as statistics lighten.
    Gilden D
    GMHC Treat Issues; 1998 Mar; 12(3):1-5. PubMed ID: 11365390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen.
    van Rij RP; van Praag RM; Prins JM; Rientsma R; Jurriaans S; Lange JM; Schuitemaker H
    Antivir Ther; 2002 Mar; 7(1):37-41. PubMed ID: 12008786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third phase of HIV decay measured.
    Bartnof HS
    BETA; 1997 Sep; ():47-8. PubMed ID: 11364703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.